Literature DB >> 32690948

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

Mark M Pomerantz1, Xintao Qiu1, Yanyun Zhu2, David Y Takeda1,3, Wenting Pan1, Sylvan C Baca1, Alexander Gusev1, Keegan D Korthauer4, Tesa M Severson2, Gavin Ha5, Srinivas R Viswanathan1, Ji-Heui Seo1, Holly M Nguyen6, Baohui Zhang7,8, Bogdan Pasaniuc9,10, Claudia Giambartolomei9,10, Sarah A Alaiwi1, Connor A Bell1, Edward P O'Connor1, Matthew S Chabot1, David R Stillman1, Rosina Lis1, Alba Font-Tello1, Lewyn Li1, Paloma Cejas1, Andries M Bergman2,11,12, Joyce Sanders13, Henk G van der Poel12, Simon A Gayther14, Kate Lawrenson14,15, Marcos A S Fonseca14,15, Jessica Reddy14,15, Rosario I Corona14,15, Gleb Martovetsky16, Brian Egan16, Toni Choueiri1, Leigh Ellis17, Isla P Garraway7,8, Gwo-Shu Mary Lee1, Eva Corey6, Henry W Long1, Wilbert Zwart18,19, Matthew L Freedman20,21.   

Abstract

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the dependency of PCa cells on the androgen receptor (AR), a prostate master transcription factor. We generated 268 epigenomic datasets spanning two state transitions-from normal prostate epithelium to localized PCa to metastases-in specimens derived from human tissue. We discovered that reprogrammed AR sites in metastatic PCa are not created de novo; rather, they are prepopulated by the transcription factors FOXA1 and HOXB13 in normal prostate epithelium. Reprogrammed regulatory elements commissioned in metastatic disease hijack latent developmental programs, accessing sites that are implicated in prostate organogenesis. Analysis of reactivated regulatory elements enabled the identification and functional validation of previously unknown metastasis-specific enhancers at HOXB13, FOXA1 and NKX3-1. Finally, we observed that prostate lineage-specific regulatory elements were strongly associated with PCa risk heritability and somatic mutation density. Examining prostate biology through an epigenomic lens is fundamental for understanding the mechanisms underlying tumor progression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32690948     DOI: 10.1038/s41588-020-0664-8

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  93 in total

1.  Sequence analysis of mutations and translocations across breast cancer subtypes.

Authors:  Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareno; Kristin K Brown; Scott L Carter; Abbie M Frederick; Michael S Lawrence; Andrey Y Sivachenko; Carrie Sougnez; Lihua Zou; Maria L Cortes; Juan C Fernandez-Lopez; Shouyong Peng; Kristin G Ardlie; Daniel Auclair; Veronica Bautista-Piña; Fujiko Duke; Joshua Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C Onofrio; Melissa Parkin; Nam H Pho; Valeria Quintanar-Jurado; Alex H Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra L Romero-Cordoba; Steven E Schumacher; Nicolas Stransky; Kristin M Thompson; Laura Uribe-Figueroa; Jose Baselga; Rameen Beroukhim; Kornelia Polyak; Dennis C Sgroi; Andrea L Richardson; Gerardo Jimenez-Sanchez; Eric S Lander; Stacey B Gabriel; Levi A Garraway; Todd R Golub; Jorge Melendez-Zajgla; Alex Toker; Gad Getz; Alfredo Hidalgo-Miranda; Matthew Meyerson
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

2.  A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.

Authors:  Han Chen; Chunyan Li; Xinxin Peng; Zhicheng Zhou; John N Weinstein; Han Liang
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

3.  Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Authors:  Jae-Seok Roe; Chang-Il Hwang; Tim D D Somerville; Joseph P Milazzo; Eun Jung Lee; Brandon Da Silva; Laura Maiorino; Hervé Tiriac; C Megan Young; Koji Miyabayashi; Dea Filippini; Brianna Creighton; Richard A Burkhart; Jonathan M Buscaglia; Edward J Kim; Jean L Grem; Audrey J Lazenby; James A Grunkemeyer; Michael A Hollingsworth; Paul M Grandgenett; Mikala Egeblad; Youngkyu Park; David A Tuveson; Christopher R Vakoc
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

4.  Punctuated evolution of prostate cancer genomes.

Authors:  Sylvan C Baca; Davide Prandi; Michael S Lawrence; Juan Miguel Mosquera; Alessandro Romanel; Yotam Drier; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Mahmoud Ghandi; Eliezer Van Allen; Gregory V Kryukov; Andrea Sboner; Jean-Philippe Theurillat; T David Soong; Elizabeth Nickerson; Daniel Auclair; Ashutosh Tewari; Himisha Beltran; Robert C Onofrio; Gunther Boysen; Candace Guiducci; Christopher E Barbieri; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Alex H Ramos; Wendy Winckler; Michelle Cipicchio; Kristin Ardlie; Philip W Kantoff; Michael F Berger; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Olivier Elemento; Gad Getz; Francesca Demichelis; Mark A Rubin; Levi A Garraway
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

Review 5.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Authors:  Manfred Kunz; Henry Löffler-Wirth; Michael Dannemann; Edith Willscher; Gero Doose; Janet Kelso; Tina Kottek; Birgit Nickel; Lydia Hopp; Jenny Landsberg; Steve Hoffmann; Thomas Tüting; Paola Zigrino; Cornelia Mauch; Jochen Utikal; Mirjana Ziemer; Hans-Joachim Schulze; Michael Hölzel; Alexander Roesch; Susanne Kneitz; Svenja Meierjohann; Anja Bosserhoff; Hans Binder; Manfred Schartl
Journal:  Oncogene       Date:  2018-07-11       Impact factor: 9.867

Review 8.  New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.

Authors:  Anushka Dongre; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2019-02       Impact factor: 94.444

9.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.

Authors:  Mark M Pomerantz; Fugen Li; David Y Takeda; Romina Lenci; Apurva Chonkar; Matthew Chabot; Paloma Cejas; Francisca Vazquez; Jennifer Cook; Ramesh A Shivdasani; Michaela Bowden; Rosina Lis; William C Hahn; Philip W Kantoff; Myles Brown; Massimo Loda; Henry W Long; Matthew L Freedman
Journal:  Nat Genet       Date:  2015-10-12       Impact factor: 38.330

10.  Progesterone receptor modulates ERα action in breast cancer.

Authors:  Hisham Mohammed; I Alasdair Russell; Rory Stark; Oscar M Rueda; Theresa E Hickey; Gerard A Tarulli; Aurelien A Serandour; Aurelien A A Serandour; Stephen N Birrell; Alejandra Bruna; Amel Saadi; Suraj Menon; James Hadfield; Michelle Pugh; Ganesh V Raj; Gordon D Brown; Clive D'Santos; Jessica L L Robinson; Grace Silva; Rosalind Launchbury; Charles M Perou; John Stingl; Carlos Caldas; Wayne D Tilley; Jason S Carroll
Journal:  Nature       Date:  2015-07-08       Impact factor: 49.962

View more
  57 in total

1.  Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms.

Authors:  Anamay Shetty; Ji-Heui Seo; Connor A Bell; Edward P O'Connor; Mark M Pomerantz; Matthew L Freedman; Alexander Gusev
Journal:  Am J Hum Genet       Date:  2021-10-25       Impact factor: 11.025

2.  Limiting Self-Renewal of the Basal Compartment by PKA Activation Induces Differentiation and Alters the Evolution of Mammary Tumors.

Authors:  Nevena B Ognjenovic; Meisam Bagheri; Gadisti Aisha Mohamed; Ke Xu; Youdinghuan Chen; Mohamed Ashick Mohamed Saleem; Meredith S Brown; Shivashankar H Nagaraj; Kristen E Muller; Scott A Gerber; Brock C Christensen; Diwakar R Pattabiraman
Journal:  Dev Cell       Date:  2020-10-28       Impact factor: 12.270

3.  EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

Authors:  Katherine L Morel; Anjali V Sheahan; Deborah L Burkhart; Sylvan C Baca; Nadia Boufaied; Yin Liu; Xintao Qiu; Israel Cañadas; Kevin Roehle; Max Heckler; Carla Calagua; Huihui Ye; Constantia Pantelidou; Phillip Galbo; Sukanya Panja; Antonina Mitrofanova; Scott Wilkinson; Nichelle C Whitlock; Shana Y Trostel; Anis A Hamid; Adam S Kibel; David A Barbie; Atish D Choudhury; Mark M Pomerantz; Christopher J Sweeney; Henry W Long; David J Einstein; Geoffrey I Shapiro; Stephanie K Dougan; Adam G Sowalsky; Housheng Hansen He; Matthew L Freedman; Steven P Balk; Massimo Loda; David P Labbé; Brian M Olson; Leigh Ellis
Journal:  Nat Cancer       Date:  2021-03-22

4.  Landscape of allele-specific transcription factor binding in the human genome.

Authors:  Sergey Abramov; Alexandr Boytsov; Daria Bykova; Dmitry D Penzar; Ivan Yevshin; Semyon K Kolmykov; Marina V Fridman; Alexander V Favorov; Ilya E Vorontsov; Eugene Baulin; Fedor Kolpakov; Vsevolod J Makeev; Ivan V Kulakovskiy
Journal:  Nat Commun       Date:  2021-05-12       Impact factor: 14.919

5.  BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.

Authors:  Dae-Hwan Kim; Duanchen Sun; William K Storck; Katherine Welker Leng; Chelsea Jenkins; Daniel J Coleman; David Sampson; Xiangnan Guan; Anbarasu Kumaraswamy; Eva S Rodansky; Joshua A Urrutia; Jacob A Schwartzman; Chao Zhang; Himisha Beltran; Mark P Labrecque; Colm Morrissey; Jared M Lucas; Ilsa M Coleman; Peter S Nelson; Eva Corey; Samuel K Handelman; Jonathan Z Sexton; Rahul Aggarwal; Wassim Abida; Felix Y Feng; Eric J Small; Daniel E Spratt; Armand Bankhead; Arvind Rao; Emily M Gesner; Sarah Attwell; Sanjay Lakhotia; Eric Campeau; Joel A Yates; Zheng Xia; Joshi J Alumkal
Journal:  Clin Cancer Res       Date:  2021-06-18       Impact factor: 12.531

6.  Developmental estrogenization: Prostate gland reprogramming leads to increased disease risk with aging.

Authors:  Gail S Prins
Journal:  Differentiation       Date:  2021-01-07       Impact factor: 3.880

7.  Developmental cell programs are co-opted in inflammatory skin disease.

Authors:  Gary Reynolds; Peter Vegh; James Fletcher; Elizabeth F M Poyner; Emily Stephenson; Issac Goh; Rachel A Botting; Ni Huang; Bayanne Olabi; Anna Dubois; David Dixon; Kile Green; Daniel Maunder; Justin Engelbert; Mirjana Efremova; Krzysztof Polański; Laura Jardine; Claire Jones; Thomas Ness; Dave Horsfall; Jim McGrath; Christopher Carey; Dorin-Mirel Popescu; Simone Webb; Xiao-Nong Wang; Ben Sayer; Jong-Eun Park; Victor A Negri; Daria Belokhvostova; Magnus D Lynch; David McDonald; Andrew Filby; Tzachi Hagai; Kerstin B Meyer; Akhtar Husain; Jonathan Coxhead; Roser Vento-Tormo; Sam Behjati; Steven Lisgo; Alexandra-Chloé Villani; Jaume Bacardit; Philip H Jones; Edel A O'Toole; Graham S Ogg; Neil Rajan; Nick J Reynolds; Sarah A Teichmann; Fiona M Watt; Muzlifah Haniffa
Journal:  Science       Date:  2021-01-22       Impact factor: 47.728

8.  Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis.

Authors:  Bo Ye; Dandan Fan; Weiwei Xiong; Min Li; Jian Yuan; Qi Jiang; Yuting Zhao; Jianxiang Lin; Jie Liu; Yilv Lv; Xiongjun Wang; Zhigang Li; Jianzhong Su; Yunbo Qiao
Journal:  Nat Commun       Date:  2021-07-22       Impact factor: 14.919

Review 9.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11

10.  A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.

Authors:  Erik Bovinder Ylitalo; Elin Thysell; Mattias Landfors; Sofie Degerman; Pernilla Wikström; Maria Brattsand; Emma Jernberg; Sead Crnalic; Anders Widmark; Magnus Hultdin; Anders Bergh
Journal:  Clin Epigenetics       Date:  2021-06-30       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.